REMEGEN announced its performance for the first three quarters, with a net loss attributable to the parent company of approximately 551 million yuan, narrowing by 48.6% year-on-year
RemeGen announced its performance for the first three quarters of 2025, with operating revenue of approximately 1.72 billion yuan, a year-on-year increase of 42.27%; the net loss attributable to the parent company was approximately 551 million yuan, a year-on-year narrowing of 48.6%. The basic loss per share was 1.01 yuan. The reduction in net loss was mainly due to increased product sales revenue, decreased R&D expenses, and a licensing agreement signed with the U.S. company Vor Bio, which led to a reduction in overseas clinical costs
According to the Zhitong Finance APP, RemeGen (09995) announced its performance for the first three quarters of 2025, with operating revenue of approximately 1.72 billion yuan, a year-on-year increase of 42.27%; the net loss attributable to shareholders of the listed company was approximately 551 million yuan, a year-on-year narrowing of 48.6%; basic loss per share was 1.01 yuan.
The announcement stated that the reduction in net loss was mainly due to a significant increase in product sales revenue, as well as the optimization of the company's R&D pipeline, leading to a decrease in various R&D expenses. Additionally, the company entered into a licensing agreement with the U.S. company Vor Bio, granting them a paid license for the independently developed TaiTasiPu. Vor Bio will obtain exclusive rights to develop and commercialize TaiTasiPu globally, excluding the Greater China region, which has resulted in a reduction in overseas clinical costs for TaiTasiPu, thereby significantly decreasing the losses for the year
